DUBLIN–()–The “Ligelizumab Emerging Drug Insight and Market Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering.

“Ligelizumab Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about Ligelizumab for Food Allergy in the 7MM. A detailed picture of the Ligelizumab for Food Allergy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Ligelizumab for Food Allergy.
The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Ligelizumab market forecast, analysis for Food Allergy in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Food Allergy.
Drug Summary
Ligelizumab (QGE031), a humanized anti-IgE antibody developed by Novartis, is a next-generation monoclonal anti-immunoglobulin E (IgE) antibody. It is also directed against C-3, but is designed to achieve improved IgE suppression, with an equilibrium dissociation constant (KD) of 139-pM (as compared to the KD of omalizumab, ~6-8 nm).
Ligelizumab’s mechanism of action involves blocking the IgE/Fc-RI pathway, a key driver of the inflammatory process in CSU (chronic spontaneous urticaria), and binding with high affinity to the C-3 domain of IgE.
Scope of the Report
Ligelizumab Analytical Perspective
In-depth Ligelizumab Market Assessment
This report provides a detailed market assessment of Ligelizumab in Food Allergy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.
Ligelizumab Clinical Assessment
The report provides the clinical trials information of Ligelizumab for Food Allergy covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
Key Questions Answered
Key Topics Covered:
1. Report Introduction
2. Ligelizumab Overview in Food Allergy
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical Studies
2.2.2. Clinical Trials Information
2.3. Other Development Activities
2.4. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. Ligelizumab Market Assessment
5.1. Market Outlook of Ligelizumab in Food Allergy
5.2. 7MM Market Analysis
5.2.1. Market Size of Ligelizumab in the 7MM for Food Allergy
5.3. Country-wise Market Analysis
5.3.1. Market Size of Ligelizumab in the United States for Food Allergy
5.3.2. Market Size of Ligelizumab in Germany for Food Allergy
5.3.3. Market Size of Ligelizumab in France for Food Allergy
5.3.4. Market Size of Ligelizumab in Italy for Food Allergy
5.3.5. Market Size of Ligelizumab in Spain for Food Allergy
5.3.6. Market Size of Ligelizumab in the United Kingdom for Food Allergy
5.3.7. Market Size of Ligelizumab in Japan for Food Allergy
6. SWOT Analysis
7. Analysts’ Views
For more information about this report visit https://www.researchandmarkets.com/r/z7z6oq
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

source

Shop Sephari